Organigram Global (NASDAQ:OGI) Releases Earnings Results, Meets Expectations

Organigram Global (NASDAQ:OGI) issued its earnings results on Tuesday. The company reported ($0.01) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.01), Zacks reports. The business had revenue of $42.99 million for the quarter, compared to analyst estimates of $50.56 million. Organigram Global had a negative net margin of 9.22% and a negative return on equity of 13.49%.

Here are the key takeaways from Organigram Global’s conference call:

• OrganiGram reported a challenging Q2, with net revenue of CAD 59.8 million, down about 9% year over year, as execution issues in vapes and infused pre-rolls weighed on results.
• Adjusted gross margin fell to 31% and adjusted EBITDA dropped to CAD 0.9 million, reflecting weaker mix, higher returns, and lower recreational revenue. Net loss also included a CAD 5.8 million impairment tied to the company’s U.S. hemp-derived products business.
• Management said the main operational problems in pre-rolls and vapes have been identified and remediated, and they are already seeing improving quality and competitiveness. They expect recovery to continue in Q3 and Q4, alongside seasonal tailwinds.
• The company emphasized strong underlying performance in other categories, including flower share gains, continued strength in edibles, beverages, and concentrates, and a record quarterly harvest of over 32,000 kilograms. OrganiGram also said its cultivation yields and genetics work are lowering costs and improving efficiency.
• Management expects the Sanity Group acquisition to drive a meaningful step-up in the second half of fiscal 2026, supporting international growth, especially in Germany and other European markets. Reflecting this, OrganiGram raised guidance to net revenue above CAD 350 million, with adjusted EBITDA and adjusted gross margin above FY2025 levels and free cash flow near breakeven.

Organigram Global Stock Performance

NASDAQ OGI remained flat at $1.12 on Thursday. 252,803 shares of the company’s stock traded hands, compared to its average volume of 755,894. Organigram Global has a 1 year low of $1.09 and a 1 year high of $2.24. The stock has a market cap of $156.96 million, a PE ratio of -8.58 and a beta of 1.50. The firm’s 50 day simple moving average is $1.39 and its 200-day simple moving average is $1.53.

Institutional Trading of Organigram Global

A number of large investors have recently added to or reduced their stakes in the business. Tidal Investments LLC boosted its holdings in Organigram Global by 4.9% during the second quarter. Tidal Investments LLC now owns 2,646,879 shares of the company’s stock worth $3,573,000 after buying an additional 124,356 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in Organigram Global by 43.2% during the fourth quarter. Renaissance Technologies LLC now owns 1,405,348 shares of the company’s stock worth $2,361,000 after buying an additional 423,900 shares in the last quarter. Millennium Management LLC bought a new stake in Organigram Global during the fourth quarter worth approximately $1,260,000. Goldman Sachs Group Inc. boosted its holdings in Organigram Global by 82.1% during the fourth quarter. Goldman Sachs Group Inc. now owns 466,585 shares of the company’s stock worth $784,000 after buying an additional 210,391 shares in the last quarter. Finally, Two Sigma Investments LP purchased a new stake in shares of Organigram Global in the 3rd quarter valued at approximately $907,000. 34.63% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Wall Street Zen lowered shares of Organigram Global from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. ATB Cormark Capital Markets lowered shares of Organigram Global from a “strong-buy” rating to a “moderate buy” rating in a research note on Wednesday, February 11th. Finally, Canaccord Genuity Group began coverage on shares of Organigram Global in a research note on Tuesday, January 27th. They set a “buy” rating on the stock. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold”.

About Organigram Global

Organigram Global Inc (NASDAQ: OGI) is a licensed producer of cannabis and hemp products headquartered in Moncton, New Brunswick, Canada. Founded in 2013, the company operates a state-of-the-art cultivation and manufacturing facility spanning more than one million square feet. Organigram holds licenses from Health Canada to produce and sell both medical and adult-use cannabis, and it pursues Good Manufacturing Practice (GMP) certification to support international exports.

The company’s product portfolio encompasses dried flower, pre-rolled joints, cannabis oils, capsules and soft gels, as well as vapourizer cartridges and extracts.